A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)

Gynecologic Oncology

Volumn 96, Issue 2, 2005, Pages 444-451

  Du Bois, A ^a   Belau, A ^b   Wagner, U ^c   Pfisterer, J ^d   Schmalfeldt, B ^e   Richter, B ^f   Staehle, A ^g   Jackisch, C ^h   Lueck, H J ⁱ   Schroeder, W ^j   Burges, A ^k   Olbricht, S ^l   Elser, G ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g St Vincentius Hospital   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j KLINIKUM BREMEN MITTE   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l OTTO VON GUERICKE UNIVERSITY   (Germany)

more..

Author keywords

Carboplatin; Chemotherapy; Epithelial ovarian cancer; Gemcitabine; Paclitaxel

Indexed keywords

CARBOPLATIN; CLEMASTINE; DEXAMETHASONE; GEMCITABINE; PACLITAXEL; RANITIDINE; SEROTONIN ANTAGONIST;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PAIN; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS; TIME SERIES ANALYSIS; TREATMENT WITHDRAWAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 19944431264     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.10.020     Document Type: Article

References (33)

1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland, 3 erw. Aufl., Saarbrücken, 2002.
2. E. Wiltshaw, S. Subramanian, and C. Alexopoulos Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum (II) at the Royal Marsden Hospital Cancer Treat. Rep. 63 1979 1545 1548
3. G. Omura, J.A. Blessing, and C.E. Ehrlich A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecological Oncology Group study Cancer 57 1986 1725 1730
4. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
5. M.J. Piccart, K. Bertelsen, and K. James Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three years results J. Natl. Cancer Inst. 92 2000 699 708
6. C. Mangioni, G. Bolis, and S. Pecorelli Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin J. Natl. Cancer Inst. 81 1989 1464 1471
7. M. Adams, I.J. Kerby, and I. Rocker A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer group Acta Oncol. 28 1989 57 60
8. A. du Bois, W. Vach, C. Thomssen, C. Karck, H. Madjar, and H.G. Meerpohl Comparison of the emetogenic potential between cisplatin and carboplatin Acta Oncol. 33 1994 531 535
9. A. du Bois, H.J. Lück, and W. Meier A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J. Natl. Cancer Inst. 95 2003 1320 1329
10. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. A Gynecologic Oncology Group study J. Clin. Oncol. 21 2003 3194 3200
11. J.P. Neijt, S.A. Engelholm, and M.K. Tuxen Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J. Clin. Oncol. 18 2000 3084 3092
12. T. Bauknecht, G.P. Breitbach, and A. du Bois Maligne ovarialtumorenin Deutsche Krebsgesellschaft e.V., Qualitätssicherung in der Onkologie, kurzgefasste interdisziplinäre Leitlinien 2000 2000 Zuckschwerdt Verlag München 301 318
13. J.S. Berek, K. Bertelsen, and A. du Bois Advanced epithelial ovarian cancer: 1998 consensus statements Ann. Oncol. 1 Suppl 10 1999 s87 s92
14. M.J. Piccart, A. du Bois, and M.E. Gore Consensus statement: a new standard of care for treatment of ovarian cancer Eur. J. Cancer 36 2000 10 12
15. A. duBois, B. Weber, and J. Pfisterer Epirubicin/paclitaxel/carboplatin (TEC) vs. paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB-IV. Interim results of an AGO-GINECO intergroup phase III trial Proc. Am. Soc. Clin. Oncol. 20 2001 202a [abstr]
16. J. Pfisterer, A. Lortholary, and R. Kimmig Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TC-TOP) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of a Gynecologic Cancer Intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO Proc. Am. Soc. Clin. Oncol. 22 2003 446 [abstr]
17. G. D'Agostino, F. Amant, P. Berteloot, G. Scambia, and I. Vergote Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer Gynecol. Oncol. 88 2003 266 269
18. M. Friedlander, M.J. Millward, and D. Bell A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer Ann. Oncol. 9 1998 1343 1345
19. B. Lund, O.P. Hansen, K. Theilade, M. Hansen, and J.P. Neijt Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients J. Natl. Cancer Inst. 86 1994 1530 1533
20. M. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer Gynecol. Oncol. 90 2003 593 596
21. G. von Minckwitz, T. Bauknecht, C.M. Visseren-Grul, and J.P. Neijt Phase II study of gemcitabine in ovarian cancer Ann. Oncol. 10 1999 853 855
22. R.S. Go, and A.A. Adjei Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin J. Clin. Oncol. 17 1999 409 422
23. P.B. Schiff, J. Fant, and S.B. Horowitz Promotion of microtubule assembly in vitro by taxol Nature 227 1979 665 667
24. W. Plunkett, P. Huang, and Y.Z. Xu Gemcitabine: metabolism, mechanisms of action, and self-potentiation Semin. Oncol. 22 Suppl 11 1995 3 10
25. P. Geertsen, M. Hansen, and I. Stoyer Combination chemotherapy with platinum, paclitaxel, and gemcitabine in patients with relapsed ovarian carcinoma Proc. Am. Soc. Clin. Oncol. 18 1999 361a [abstr 1395]
26. C.J. Poole, S.D. Jordan, and H.B. Higgins A phase I intra and interpatient dose ranging trial of gemcitabine, carboplatin, and paclitaxel (GCP) in combination in previously untreated patients with epithelial ovarian cancer, primary peritoneal malignancy, ovarian carcinosarcoma and fallopian tube carcinoma Proc. Am. Soc. Clin. Oncol. 20 2001 220a [abstr 878]
27. S.W. Hansen, H. Anderson, and K. Boman Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV Proc. Am. Soc. Clin. Oncol. 18 1999 357a [abstr 1379]
28. R.W. Jeliffe Creatinine clearance: bedside estimate Ann. Intern. Med. 79 1973 604 [letter]
29. A.H. Calvert, D.R. Newell, and L.A. Gumbrell Carboplatin dosage: prospective evaluation of a simple formula based on renal function J. Clin. Oncol. 7 1989 1748 1756
30. World Health Organization WHO handbook for reporting results of cancer treatment 1979 World Health Organization Geneva, Switzerland Offset Publication No. 40
31. J.P. Micha, B.H. Goldstein, M.A. Rettenmaier, J. Mattison, C. Graham, and C.L. Birk Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer Gynecol. Oncol. 94 2004 719 724
32. D.F. Roychowdhury, C.A. Cassidy, P. Peterson, and M. Arning A report on serious pulmonary toxicity associated with gemcitabine-based therapy Investigational New Drugs 20 2002 311 315
33. K.Y. Look, M.A. Bookman, J. Schol, T.J. Herzog, T. Rocereto, and J. Vinters Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 92 2004 93 100